The drugmaker filed for bankruptcy in September 2019 to resolve thousands of lawsuits accusing it of fueling the opioid crisis, primarily by flooding communities with its highly addictive narcotic OxyContin.
Oklahoma is the only state not involved in the lawsuit, filed Aug. 17, because it settled litigation with Purdue Pharma in 2019. Two of the country’s most populous states, California and New York, are seeking $192 billion and $165 billion, respectively.
Purdue Pharma spokespeople told CNN the high-figure claims were anticipated and that the company denied any wrongdoing.
“On July 30, Purdue successfully concluded one of the most extensive noticing campaigns in chapter 11 history,” Michele Sharp, Purdue’s executive director of media relations, said in a statement. “Purdue continues its work to emerge from bankruptcy, garner additional support for the proposed settlement, and implement a final resolution.”
Purdue Pharma’s proposed settlement offers a valuation more than $10 billion in value, which includes the entirety of its assets.
More articles on opioids:
FDA to require information about naloxone on opioid labels
APhA, Walmart team up to offer free opioid stewardship program
Pregnant women face obstacles in obtaining opioid use disorder treatment, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
